Skip to main content
KOD
NASDAQ Life Sciences

Baker Bros. Buys $24.3M of Kodiak Sciences at $98.51, Adding to 20.4M-Share Stake

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$99.3
Mkt Cap
$6.241B
52W Low
$15.833
52W High
$104
52W Position info
527% above low
Off High info
4.5% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

KOD has more than doubled off its 52-week low of $15.833.

Summary

Baker Bros. bought 247,090 Kodiak Sciences shares for $24.3 million at $98.51 on November 4-5, lifting its stake to 20.4 million shares. The open-market purchase extends the firm's post-DAYBREAK accumulation.


Key Events · Ownership and Investor Activity · KOD

  • Baker Bros. Adds 247,090 Shares

    Baker Bros. Advisors and affiliates bought 247,090 shares for $24,340,836 at $98.51 across four transactions on 2026-11-04 and 2026-11-05.

  • Stake Reaches 20.4 Million Shares

    Post-transaction holdings total 20,424,859 shares, held indirectly through 667, L.P. and Baker Brothers Life Sciences, L.P.

  • Follows September Accumulation

    Comes after the group's $58.6 million purchase reported 2026-09-30, the day Kodiak disclosed positive DAYBREAK Phase 3 results.

  • Going-Concern Risk Persists

    The Q2 2026 10-Q reiterated that cash of $125.9 million may not cover the next 12 months; a new $350 million at-the-market program was registered 2026-10-20.


Analysis · KOD · Life Sciences

Baker Bros. Advisors and affiliates, including director and 10% owner Julian Baker, bought 247,090 shares for $24.3 million at $98.51 on November 4-5. This is real open-market cash, not an option exercise, and it extends a pattern of accumulation: the same group bought $58.6 million in late September after the DAYBREAK Phase 3 win. The purchase is modest relative to Kodiak's roughly $6.2 billion market value, but it shows the largest holder still adding near the 52-week high of $104. The main risk remains the going-concern warning from the Q2 10-Q, which said cash may not cover the next 12 months; the new $350 million at-the-market program registered October 20 is the likely funding backstop.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, KOD was trading at $99.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.2B. The 52-week trading range was $15.83 to $104.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

KOD - Latest Insights

KOD
Nov 12, 2026, 4:00 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $108.12
Real-time Price: $97.26 info
Change: -$10.86 (-10%) info
Market Cap: $6.354B info
KOD
Nov 12, 2026, 4:00 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $108.25
Real-time Price: $97.26 info
Change: -$10.99 (-10%) info
Market Cap: $6.354B info
KOD
Oct 20, 2026, 5:19 PM EDT
Filing Type: S-3ASR
Importance Score:
7
Price at Filing: $92.97
Real-time Price: $97.26 info
Change: +$4.29 (+5%) info
Market Cap: $6.354B info
KOD
Sep 30, 2026, 4:29 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $94.50
Real-time Price: $97.26 info
Change: +$2.76 (+3%) info
Market Cap: $6.354B info
KOD
Sep 28, 2026, 8:53 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $60.69
Real-time Price: $97.26 info
Change: +$36.57 (+60%) info
Market Cap: $6.354B info